BioGend Therapeutics Statistics

Total Valuation

TPEX:6733 has a market cap or net worth of TWD 3.94 billion. The enterprise value is 3.36 billion.

Market Cap	3.94B
Enterprise Value	3.36B

Important Dates

The next estimated earnings date is Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

TPEX:6733 has 124.26 million shares outstanding. The number of shares has increased by 2.32% in one year.

Current Share Class	n/a
Shares Outstanding	124.26M
Shares Change (YoY)	+2.32%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.11%
Owned by Institutions (%)	2.56%
Float	74.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.27
PB Ratio	4.82
P/TBV Ratio	5.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-28.83
EV / Sales	20.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-33.73

Financial Position

The company has a current ratio of 21.60, with a Debt / Equity ratio of 0.01.

Current Ratio	21.60
Quick Ratio	21.06
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	-568.65

Financial Efficiency

Return on equity (ROE) is -13.30% and return on invested capital (ROIC) is -8.37%.

Return on Equity (ROE)	-13.30%
Return on Assets (ROA)	-7.78%
Return on Invested Capital (ROIC)	-8.37%
Return on Capital Employed (ROCE)	-13.90%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.17
Inventory Turnover	2.29

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.36% in the last 52 weeks. The beta is 0.61, so TPEX:6733's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	-16.36%
50-Day Moving Average	32.96
200-Day Moving Average	35.63
Relative Strength Index (RSI)	41.85
Average Volume (20 Days)	119,142

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6733 had revenue of TWD 167.65 million and -116.47 million in losses. Loss per share was -0.95.

Revenue	167.65M
Gross Profit	130.51M
Operating Income	-122.26M
Pretax Income	-128.25M
Net Income	-116.47M
EBITDA	-74.76M
EBIT	-122.26M
Loss Per Share	-0.95

Full Income Statement

Balance Sheet

The company has 619.02 million in cash and 9.43 million in debt, giving a net cash position of 609.59 million or 4.91 per share.

Cash & Cash Equivalents	619.02M
Total Debt	9.43M
Net Cash	609.59M
Net Cash Per Share	4.91
Equity (Book Value)	846.51M
Book Value Per Share	6.58
Working Capital	684.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -98.91 million and capital expenditures -650,000, giving a free cash flow of -99.56 million.

Operating Cash Flow	-98.91M
Capital Expenditures	-650,000
Free Cash Flow	-99.56M
FCF Per Share	-0.80

Full Cash Flow Statement

Margins

Gross margin is 77.85%, with operating and profit margins of -72.93% and -69.47%.

Gross Margin	77.85%
Operating Margin	-72.93%
Pretax Margin	-76.50%
Profit Margin	-69.47%
EBITDA Margin	-44.59%
EBIT Margin	-72.93%
FCF Margin	n/a

Dividends & Yields

TPEX:6733 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.32%
Shareholder Yield	-2.32%
Earnings Yield	-2.96%
FCF Yield	-2.53%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6733 has an Altman Z-Score of 41.78.

Altman Z-Score	41.78
Piotroski F-Score	n/a